实体瘤疗效评价标准简介

国际肿瘤学杂志››2016,Vol. 43››Issue (11): 845-847.doi:10.3760/cma.j.issn.1673-422X.2016.11.011

张百红，岳红云

730050 兰州军区总医院肿瘤科（张百红），眼科（岳红云）

收稿日期:2016-01-22出版日期:2016-11-08发布日期:2016-11-02
通讯作者:张百红，Email: bhzhang1999@126.com E-mail:bhzhang1999@126.com
基金资助:

甘肃省自然科学基金（1308RJZA181）

Brief introduction of response evaluation criteria in solid tumors

Zhang Baihong, Yue Hongyun

Department of Oncology, Lanzhou General Hospital of Lanzhou Military Region, Lanzhou 730050, China

Received:2016-01-22Online:2016-11-08Published:2016-11-02
Contact:Zhang Baihong E-mail:bhzhang1999@126.com
Supported by:

Natural Science Foundation of Gansu Province of China (1308RJZA181)

摘要/Abstract

摘要：随着靶向治疗时代的到来，新的实体瘤评价标准如改良的实体瘤反应评价标准、正电子发射断层扫描反应标准、Choi标准和免疫相关反应标准相继出现。血清标志物和循环肿瘤细胞等也用于临床反应的评价。这些指标为肿瘤疗效评价提供了有力的工具。

张百红，岳红云. 实体瘤疗效评价标准简介[J]. 国际肿瘤学杂志, 2016, 43(11): 845-847.

Zhang Baihong, Yue Hongyun. Brief introduction of response evaluation criteria in solid tumors[J]. Journal of International Oncology, 2016, 43(11): 845-847.

［1］ Hewitt SM, Badve SS, True LD, et al. Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy［J］. Clin Cancer Res, 2012, 18(6): 1524-1530. DOI: 10.1158/1078-0432.CCR-11-2204. ［2］ Sharma MR, Maitland ML, Ratain MJ. RECIST: no longer the sharpest tool in the oncology clinical trials toolboxpoint［J］. Cancer Res, 2012, 72(20): 5145-5149. DOI: 10.1158/0008-5472.CAN-12-0058. ［3］ Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma［J］. Clin Cancer Res, 2013, 19(6): 1312-1314. DOI: 10.1158/1078-0432.CCR-12-3796. ［4］ Kim BK, Kim KA, Park JY, et al. Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with European association for the study of the liver criteria in hepatocellular carcinoma following chemoembolisation［J］. Eur J Cancer, 2013, 49(4): 826-834. DOI: 10.1016/j.ejca.2012.08.022. ［5］ Bargellini I, Scionti A, Mismas V, et al. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?［J］. Oncology, 2014, 86(4): 191-198. DOI: 10.1159/000358599. ［6］ Taieb S, SaadaBouzid E, Tresch E, et al. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis［J］. Eur J Cancer, 2015, 51(2): 202-209. DOI: 10.1016/j.ejca.2014.11.008. ［7］ Ding Q, Cheng X, Yang L, et al. PET/CT evaluation of response to chemotherapy in nonsmall cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST)［J］. J Thorac Dis, 2014, 6(6): 677-683. DOI: 10.3978/j.issn.2072-1439.2014.05.10. ［8］ Skougaard K, Johannesen HH, Nielsen D, et al. CT versus FDGPET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab［J］. Cancer Med, 2014, 3(5): 1294-1301. DOI: 10.1002/cam4.271. ［9］ Ziai D, Wagner T, El Badaoui A, et al. Therapy response evaluation with FDGPET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria［J］. Cancer Imaging, 2013, 13: 73-80. DOI: 10.1102/1470-7330.2013.0008. ［10］ Stacchiotti S, Verderio P, Messina A, et al. Tumor response assessment by modified Choi criteria in localized highrisk soft tissue sarcoma treated with chemotherapy［J］. Cancer, 2012, 118(23): 5857-5866. DOI: 10.1002/cncr.27624. ［11］ Schmidt N, Hess V, Zumbrunn T, et al. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies［J］. Eur Radiol, 2013, 23(3): 632-639. DOI: 10.1007/s00330-012-2640-x. ［12］ Ronot M, Bouattour M, Wassermann J, et al. Alternative response criteria (Choi, European association for the study of the liver, and modified response evaluation criteria in solid tumors ［RECIST］) versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib［J］. Oncologist, 2014, 19(4): 394-402. DOI: 10.1634/theoncologist.2013-0114. ［13］ Kim HS, Kim JW, Kim JH, et al. Singlelesion measurement per organ for assessing tumor response in advanced gastric cancer［J］. Oncology, 2015, 88(2): 69-75. DOI: 10.1159/000367810. ［14］ Nishino M, Gargano M, Suda M, et al. Optimizing immunerelated tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?［J］. J Immunother Cancer, 2014, 2: 17. DOI: 10.1186/2051-1426-2-17. ［15］ Enooku K, Tateishi R, Kanai F, et al. Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times［J］. J Gastroenterol, 2012, 47(1): 71-78. DOI: 10.1007/s00535011-0462-2. ［16］ Alexandre J, Brown C, Coeffic D, et al. CA125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial［J］. Br J Cancer, 2012, 106(4): 633-637. DOI: 10.1038/bjc.2011.593. ［17］ Tsuchiya K, Asahina Y, Matsuda S, et al. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma［J］. Cancer, 2014, 120(2): 229-237. DOI: 10.1002/cncr.28384. ［18］ Abusaif S, Jradi Z, Held L, et al. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma［J］. Melanoma Res, 2013, 23(5): 396-401. DOI: 10.1097/CMR.0b013e3283650741. ［19］ Vishnukumar S, Umamaheswaran G, Anichavezhi D, et al. Pglycoprotein expression as a predictor of response to neoadjuvant chemotherapy in breast cancer［J］. Indian J Cancer, 2013, 50(3): 195-199. DOI: 10.4103/0019-509X.118726. ［20］ Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in nonsmall cell lung cancer: association with clinical endpoints in a phase Ⅱ clinical trial of pertuzumab and erlotinib［J］. Clin Cancer Res, 2012, 18(8): 2391-2401. DOI: 10.1158/1078-0432.CCR-11-3148. ［21］ Wallwiener M, Riethdorf S, Hartkopf AD, et al. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients［J］. BMC Cancer, 2014, 14: 512. DOI: 10.1186/1471-2407-14-512. ［22］ Najjar F, Alammar M, Bachour M, et al. Predictive and prognostic value of circulating endothelial cells in nonsmall cell lung cancer patients treated with standard chemotherapy［J］. J Cancer Res Clin Oncol, 2015, 141(1): 119-125. DOI: 10.1007/s00432-014-1778-0. ［23］ Teng FF, Meng X, Sun XD, et al. New strategy for monitoring targeted therapy: molecular imaging［J］. Int J Nanomedicine, 2013, 8: 3703-3713. DOI: 10.2147/IJN.S51264.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.